Evidence map›Paper›PMID 32019136›Full record

ArticleInternational journal of molecular sciences2020

Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.

Nurbubu T Moldogazieva, Daria S Ostroverkhova, Nikolai N Kuzmich, Vladimir V Kadochnikov, Alexander A Terentiev, Yuri B Porozov

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Recent Trends in Cancer Genomics and Bioinformatics Tools Development.International journal of molecular sciences · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. Bioinformatics Methods in Medical Genetics and Genomics.International journal of molecular sciences · 2020
    Article
  12. Alpha-fetoprotein: A Multifaceted Player in Cancer Biology.Euroasian journal of hepato-gastroenterology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nurbubu T MoldogazievaLaboratory of Bioinformatics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0002-9814-2300
Daria S OstroverkhovaLaboratory of Bioinformatics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0002-5626-4967
Nikolai N KuzmichLaboratory of Bioinformatics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0002-0305-5619
Vladimir V KadochnikovDepartment of Food Biotechnology and Engineering, Saint Petersburg National Research University of Information Technologies, Mechanics and Optics, 197101 Saint-Petersburg, Russia.ORCID 0000-0002-8734-7079
Alexander A TerentievDeparment of Biochemistry and Molecular Biology, N.I. Pirogov Russian National Research Medical University, 117997 Moscow, Russia.ORCID 0000-0001-8553-0614
Yuri B PorozovLaboratory of Bioinformatics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0002-5450-3135
Sechenov University · RUITMO University · RUPirogov Russian National Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-fetoprotein (AFP) is a major embryo- and tumor-associated protein capable of binding and transporting a variety of hydrophobic ligands, including estrogens. AFP has been shown to inhibit estrogen receptor (ER)-positive tumor growth, which can be attributed to its estrogen-binding ability. Despite AFP having long been investigated, its three-dimensional (3D) structure has not been experimentally resolved and molecular mechanisms underlying AFP-ligand interaction remains obscure. In our study, we constructed a homology-based 3D model of human AFP (HAFP) with the purpose of molecular docking of ERα ligands, three agonists (17β-estradiol, estrone and diethylstilbestrol), and three antagonists (tamoxifen, afimoxifene and endoxifen) into the obtained structure. Based on the ligand-docked scoring functions, we identified three putative estrogen- and antiestrogen-binding sites with different ligand binding affinities. Two high-affinity binding sites were located (i) in a tunnel formed within HAFP subdomains IB and IIA and (ii) on the opposite side of the molecule in a groove originating from a cavity formed between domains I and III, while (iii) the third low-affinity binding site was found at the bottom of the cavity. Here, 100 ns molecular dynamics (MD) simulation allowed us to study their geometries and showed that HAFP-estrogen interactions were caused by van der Waals forces, while both hydrophobic and electrostatic interactions were almost equally involved in HAFP-antiestrogen binding. Molecular mechanics/Generalized Born surface area (MM/GBSA) rescoring method exploited for estimation of binding free energies (ΔG

Indexed as

alpha-FetoproteinsAmino Acid SequenceAmino Acid SubstitutionBinding SitesEstradiolEstrogen Receptor alphaEstrogen Receptor ModulatorsEstrogensFemaleHumansLigandsModels, MolecularMolecular Docking SimulationMolecular Dynamics SimulationMutagenesisSequence AlignmentAFP protein, humanalpha-FetoproteinsESR1 protein, humanEstradiolEstrogen Receptor alphaEstrogen Receptor ModulatorsEstrogensLigandsalpha-fetoproteinamino acid substitutionsestrogenshomology-based modelingmolecular dockingprotein–ligand interactionselective estrogen receptor modulators

Identifiers

PMID32019136
PMCPMC7036865
OpenAlexW2997960396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.